S.J. Scherer

Biomarker results from the AVADO phase 3 trial of first-line bevacizumab plus docetaxel for HER2-negative metastatic breast cancer

D.W. Miles, Sanne Lysbet de Haas, Luc Dirix et al. · British Journal of Cancer · 2013 · 154 citations · Full text

Medicine, Oncology, Pharmacology +17

804 ORAL Evaluation of Plasma VEGFA as a Potential Predictive Pan-tumour Biomarker for Bevacizumab

Gordon C. Jayson, SL de Haas, Paul Delmar et al. · European Journal of Cancer · 2011 · 38 citations

Medicine, Cancer Biology, Oncology +16

803 ORAL Analysis of Blood Plasma Factors in the AVITA Phase III Randomized Study of Bevacizumab (bev) With Gemcitabine-Erlotinib (GE) in Patients (pts) With Metastatic Pancreatic Cancer (mPC)

Eric Van Cutsem, Gordon C. Jayson, Caroline Dive et al. · European Journal of Cancer · 2011 · 30 citations

Medicine, Oncology, Pharmacology +13

1414 POSTER Single Nucleotide Polymorphism Analysis and Outcome in Advanced-stage Cancer Patients Treated With Bevacizumab

Diether Lambrechts, Paul Delmar, D.W. Miles et al. · European Journal of Cancer · 2011 · 12 citations

Medicine, Genetics, Oncology +13

Biomarker (BM) Results from GOG-0218, a Phase 3 Trial of Front-Line Bevacizumab (BV) + Chemotherapy (CT) for Ovarian Cancer (OC)

M. J. Birrer, Heather A. Lankes, Robert A. Burger et al. · Annals of Oncology · 2012 · 10 citations

Medicine, Gynecology, Oncology +16